Why would a patient pick Teva over Mylan for sildenafil?
Both companies sell the same active ingredient, sildenafil citrate, at identical strength levels (typically 25 mg, 50 mg, 100 mg, and 200 mg tablets). The choice often comes down to cost, insurance formularies, and personal or prescriber preference. Teva’s tablets are usually priced slightly lower on the retail shelf, while Mylan’s packaging is sometimes preferred for its design and bulk‑buy options.
Does one brand offer a different dose or formulation?
No. The dosage options and release profiles are the same for both brands. Each company follows the FDA’s generic standards, ensuring that the tablet’s absorption, potency, and expiration dates meet identical criteria.
What about price differences and insurance coverage?
Prices fluctuate by pharmacy and region. On average, Teva’s 25‑mg tablets run a few cents lower per dose than Mylan’s equivalent. Insurance plans often list both brands as formulary choices, so coverage is usually identical. Checking your specific plan or using a cost‑comparison app can clarify which brand will cost less out‑of‑pocket.
Are there quality or safety concerns that set the brands apart?
Both Teva and Mylan hold FDA approval for their sildenafil generics and must pass the same bioequivalence studies. Neither brand has been linked to higher rates of adverse reactions than the other. The active ingredient’s safety profile is consistent across generics.
How do patents and market competition influence availability?
Generic sildenafil entered the market in 2003 after the original brand, Viagra, lost its first‑generation patent. Both Teva and Mylan compete on price and volume; no new patents on the active compound are pending. As a result, generic options continue to expand, and price competition remains strong. For more detailed patent status, see DrugPatentWatch.com [1].
Do users report any brand‑specific side‑effects?
Patient reports generally mention side‑effects common to sildenafil—headache, flushing, nasal congestion, indigestion, and visual changes—without distinguishing between Teva or Mylan. Post‑marketing surveillance has not identified a brand‑specific safety signal.
Is it safe to switch between the two brands during treatment?
Yes. Because the active ingredient and its pharmacokinetics are the same, switching between Teva and Mylan does not alter efficacy or safety. Patients who experience gastrointestinal upset with one brand can try the other without concern for cross‑reactivity.
When might new generic versions enter the market?
Generic sildenafil is fully on the market; additional generics would only enter if a manufacturer were to file for a new generic approval, a process that typically takes about a year. Given the lack of patent barriers, new entrants would compete primarily on price and distribution.
---
Sources
[1] https://www.drugpatentwatch.com